[Skip to Content]
[Skip to Content Landing]
July 17, 1981

Posttransfusion Hepatitis in Acute Myelogenous Leukemia-Reply

Author Affiliations

University of California Los Angeles School of Medicine

JAMA. 1981;246(3):216. doi:10.1001/jama.1981.03320030013015

In Reply.—  Dr Novak raises valid questions regarding accurate criteria for the diagnosis of posttransfusion hepatitis. In his own interesting manuscript (his reference 1), he, in fact, failed to define criteria for acute hepatitis clearly. In our study we chose to use criteria identical to those suggested by Barton and Conrad,1 ie, SGOT greater than 50 IU/L on two or more consecutive measurements. These authors had reported an association between hepatitis and survival, and we were interested in directly comparing our data with theirs. Our criteria do not appear to differ substantially from that used by Dr Novak (SGOT, ≥60 IU/L). Most investigators, including ourselves, would agree that those are not ideal criteria on which to base the diagnosis of hepatitis. Although the lower limit in our analysis was SGOT greater than 50 IU/L, mean peak titers in hepatitis patients were considerably higher— SGOT, 568 IU/L, and SGPT, 710